Today, AstraZeneca announce second quarter and half year results 2010.Commenting on the results, David Brennan, CEO said:
"Our second quarter performance reflects continued strong growth in our Emerging Markets and good performance for key brands Crestor, Seroquel and Symbicort. While revenue and Core EPS comparisons become more challenging in the second half of the year, we have increased our full year financial targets." |
No comments:
Post a Comment